Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression Of Hormones In Children With Premature Onset Puberty
May 15th 2008Drug InformationEndocrinology
Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty, at the Lawson Wilkins Pediatric Endocrine Society (LWPES) Annual Meeting.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
